XmAb819 Targets Highly Expressed Protein in Clear Cell Renal Cell CarcinomaByRitesh R. Kotecha, MDJuly 24th 2025An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.